Evidence map›Paper›PMID 25783477›Full record

ArticleNeuroscience2015

Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey.

A Roy, S Mondal, J H Kordower, K Pahan

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. A simple protocol for isolating microglia from adult mouse brain.NeuroImmune pharmacology and therapeutics · 2023
    Article
  9. Review
  10. Article
  11. Increased Serum Level of CCL5 in Children with Attention‑Deficit/Hyperactivity Disorder: First Results about Serum Chemokines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022
    Article
  12. Review
  13. Article
  14. T cells, α-synuclein and Parkinson disease.Handbook of clinical neurology · 2022
    Review
  15. Article
  16. Article
  17. Intranigral Administration ofJournal of immunology research · 2020
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A RoyDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States.
S MondalDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States.
J H KordowerDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States.
K PahanDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States; Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, 820 South Damen Avenue, Chicago, IL, United States. Electronic address: kalipada_pahan@rush.edu.
Rush University Medical Center · US

Funding

RANTES and Eotaxin: New players in PD progressionR01NS083054 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2013 to 2017
$1.7M
NEMO-binding domain peptide in a monkey model of PDR21NS064564 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2010 to 2011
$410k
NINDS NIH HHS NS064564NINDS NIH HHS NS083054NINDS NIH HHS R01 NS083054NINDS NIH HHS R21 NS064564
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Despite intense investigations, little is known about its pathological mediators. Here, we report the marked upregulation of RANTES (regulated on activation, normal T cell expressed and secreted) and eotaxin, chemokines that are involved in T cell trafficking, in the serum of hemiparkinsonian monkeys. Interestingly, 1-methyl-4-phenylpyridinium (MPP(+)), a Parkinsonian toxin, increased the expression of RANTES and eotaxin in mouse microglial cells. The presence of NF-κB binding sites in promoters of RANTES and eotaxin and down-regulation of these genes by NEMO-binding domain (NBD) peptide, selective inhibitor of induced NF-κB activation, in MPP(+)-stimulated microglial cells suggest that the activation of NF-κB plays an important role in the upregulation of these two chemokines. Consistently, serum enzyme-linked immuno assay (ELISA) and nigral immunohistochemistry further confirmed that these chemokines were strongly upregulated in MPTP-induced hemiparkinsonian monkeys and that treatment with NBD peptides effectively inhibited the level of these chemokines. Furthermore, the microglial upregulation of RANTES in the nigra of hemiparkinsonian monkeys could be involved in the altered adaptive immune response in the brain as we observed greater infiltration of CD8(+) T cells around the perivascular niche and deep brain parenchyma of hemiparkinsonian monkeys as compared to control. The treatment of hemiparkinsonian monkeys with NBD peptides decreased the microglial expression of RANTES and attenuated the infiltration of CD8(+) T cells in nigra. These results indicate the possible involvement of chemokine-dependent adaptive immune response in Parkinsonism.

Indexed as

AnimalsAntigens, CDCalcium-Binding ProteinsCCAAT-Binding FactorCD8-Positive T-LymphocytesCells, CulturedChemokine CCL11Chemokine CCL5CytokinesDisease Models, AnimalDNA-Binding ProteinsFemaleGene Expression RegulationMacaca mulattaMiceMicrofilament ProteinsAIF1 protein, humanAntigens, CDCalcium-Binding ProteinsCCAAT-Binding FactorChemokine CCL11Chemokine CCL5CytokinesDNA-Binding ProteinsMicrofilament ProteinsNBD peptide, mouseNfyb protein, mousePeptidesTyrosine 3-Monooxygenasehemiparkinsonian monkeysmicroglianeuroinflammationParkinson’s diseaseRANTEST cell infiltration

Identifiers

PMID25783477
PMCPMC4527882
OpenAlexW2067018636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.